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Both interleukin-1 receptor (IL-1R) and toll-like recep-
tor 2 (TLR2) signal via the adapter molecule MyD88.
However, in response to a cutaneous infection chal-
lenge, the downstream signaling events diverge and
IL-1R, but not TLR2, proves to be essential for host
defense.
It is well established that toll-like receptor (TLR) ligands,
as well as interleukin-1 receptor (IL-1R) and IL-18R li-
gands, activate the MyD88 signal transduction pathway.
However, in this issue of Immunity, Miller et al. show
that the IL-1R, rather than TLR2, accounts for the acute
inflammatory response to cutaneous Staphylococcus
aureus challenge in mice (Miller et al., 2006). Only
MyD88- and IL-1R-deficient mice have a marked defect
in resolution of the cutaneous S. aureus infection with
diminished neutrophil infiltration, persistently higher
bacterial counts, and failure to eradicate the infection.
In contrast, TLR2-deficient mice exhibited only moder-
ately larger than normal lesions and minimal increases
in bacterial counts.
TLR2 signals appear to increase the rate and efficiency
of mobilization of polymorphonuclear cells, whereas
IL-1R signals are essential. Miller et al. show that
the transfer of wild-type, IL-1R-deficient, or MyD88-
deficient bone-marrow cells into irradiated wild-type
mice did not impair host responses to S. aureus infec-
tion. In contrast, reconstitution with wild-type bone mar-
row failed to correct the impaired response of IL-1R-
deficient hosts. Thus, the resident skin cells, rather than
bone-marrow-derived leukocytes, are the likely source
of IL-1a and IL-1b, which in turn stimulated the produc-
tion of high amounts of chemokine attractants for neu-
trophils such as KC and MIP2 (Figure 1).
Although IL-1R stimulation by IL-1a and IL-1b results
in a vast array of in vitro biological consequences
(Oppenheim and Gery, 1982, 1993), gene deletion of
IL-1a and IL-1b or IL-1R resulted in no developmental
phenotypic consequences (reviewed in Nakae et al.,
2003). Despite this apparent redundancy of IL-1effects,
IL-1 is unique in that it is characterized by feedback reg-
ulators in the form of a decoy IL-1R type II receptor and
IL-1RA, a selective antagonist of the functional IL-1R
type I. However, a number of reports over the past five
years have shown that IL-1 is essential for host defense
against a variety of infectious challenges, the induction
of experimental autoimmune encephelomyelitis (EAE),
and collagen-induced arthritis (Nakae et al., 2003). IL-
1b-deficient mice were somewhat resistant to fever
induction, had impaired acute phase responses to tur-
pentine treatment, and reduced delayed and contact
hypersensitivity reactions. However, IL-1R-deficient
mice exhibited greater defects and were less sensitive
to endotoxin. Depending on their genetic background,
IL-1R-deficient mice were also more susceptible to
challenge with Gram-positive Listeria monocytogenesand S. aureus organisms (Nakae et al., 2003), consistent
with the study by Miller et al.
These findings are reinforced by the opposite conse-
quences of challenging IL-1RA-deficient mice (reviewed
in Nicklin and Shepherd, 2003). Such mice spontane-
ously developed arthritis, psoriatic-like disease, and
arteritis and had a shortened life span. On the basis of
the broad expression of IL-1, IL-1R, and IL-1RA, defi-
ciencies in IL-1RA enhance both innate and adaptive
immune reactions at many sites. IL-1RA-deficient mice
spontaneously exhibit neutrophilia, some increase in
circulating CD4+ IFN-g+ T cells, and increased CD11b+
progenitors in the bone marrow. IL-1RA-deficient mice,
as predicted, are more sensitive to endotoxin or turpen-
tine treatment and more resistant to L. monocytogenes.
IL-1RA-deficient mice also develop a more severe colla-
gen-induced arthritis. Overall, long-term intermittent ex-
posure to elevated IL-1 experienced by IL-1RA-deficient
mice in response to environmental injuries and infec-
tions results in chronic rather than acute inflammatory
conditions. Although neutrophils dominate the IL-1-
dependent response to bacterial challenge, the down-
stream effects of IL-1 have the capacity to elicit lympho-
cyte-dependent adaptive immune inflammation.
A recent report shows that the MyD88 pathway is
essential for the induction of experimental autoimmune
uveitis (EAU) (Su et al., 2005). However, EAU could
readily be induced in mice that are deficient in TLR2,
TLR4, TLR9, and IL-18, but not in IL-1R-deficient mice
(Su et al., 2005). Thus, unlike MyD88-dependent TLR2,
TLR4, TLR9, and IL-18, the IL-1 signals are clearly
nonredundant.
These reports raise a number of provocative ques-
tions. What induces the production of IL-1? In the case
of the present study, IL-1a stored in skin cells is actually
expressed on keratinocyte membranes in response to
injury by cutaneous S. aureus infection. Presumably,
bacterial components activate a number of the TLRs,
in addition to TLR2 and non-TLR receptors, to make
the IL-1a available. However, because MyD88-deficient
mice still produce IL-1b, but at a slower rate, TLR-inde-
pendent pathways also contribute to IL-1b production
(Miller et al., 2006). As pointed out by the authors, al-
though IL-1 is the essential inflammatory mediator at
skin sites, tumor necrosis factor rather than IL-1 may
be the major inflammatory mediator induced in infec-
tions of the lung and peritoneum. The relative impor-
tance of various proinflammatory cytokines in various
tissues needs to be more clearly defined. Perhaps IL-1
is pre-eminent at neuroectodermal skin and brain sites.
How is it possible for IL-1R and TLR2, which both uti-
lize the MyD88 pathway, to have such divergent effects
in response to dermal infection with S. aureus? The au-
thors suggest that this could be attributed to the depen-
dence of TLR2, but not IL-1R signaling, on TIRAP (also
known as MAL) (Horng et al., 2002). However, because
both receptors are dependent on MyD88, the utilization
of the TIRAP adaptor molecule in the absence of MyD88
would therefore somehow have to interfere with the
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17Figure 1. IL-1R-MyD88 Signaling Is Pivotal
for the Development of Immunity against Sta-
phlyloccus aureus
Activation of TLR2, other TLRs, and non-TLR
receptors by S. aureus leads to the produc-
tion of IL-1. MyD88-dependent IL-1R is ex-
pressed on most cell types, whereas TLRs
are expressed on keratinocytes, Langerhans
cells, and dendritic cells. MyD88-indepen-
dent pathways are used by non-TLRs such
as leukocyte scavenger receptors and Fc re-
ceptors. Autocrine and/or paracrine signaling
via the IL-1-IL-1R-MyD88 pathway is neces-
sary to stimulate the production of MIP-2
and KC, which in turn recruit neutrophils to
the site of infection.induction of the CXC chemokines KC and MIP2 that re-
cruit neutrophils. The difference between IL-1R and
TLR2 is also unlikely to be due to IRAK-4 because this
kinase is essential for TLRs, IL-18, and IL-1 (Medvedev
et al., 2005). Furthermore, IL-1, IL-18, and TLR4 signal
through IRAK-1, and IRAK-1-deficient mice resist the in-
duction of EAE and are more sensitive to infection with
higher doses of S. aureus (Verdrengh et al., 2004). Thus,
IRAK-1 also can not account for the requirement for
IL-1. It is possible that IL-1R is more readily available
on the skin than TLR2. However, TLR2 must also be
available because TLR2-deficient mice do show a mod-
est defect in bacterial clearance. Thus, the simplest and
most likely explanation is that TLR2 signals are largely
redundant, whereas those of IL-1R are nonredundant
as proposed by Miller et al.
Why does S. aureus-induced IL-1a and IL-1b lead to
high amounts of KC and MIP2 neutrophil chemoattrac-
tants? It has been reported that IL-1 induces consider-
able expression of KC and MIP2 by different cell types
at different times (Armstrong et al., 2004). IL-1 stimu-
lates dermal fibroblasts and endothelial cells to produce
KC in the skin by 6 hr after surgery. MIP2 is produced
subsequently by infiltrating neutrophils and monocytes.
These responses are based on increases in gene tran-
scription rather than message stabilization. Presum-
ably, IL-1 induces transcription factors that interact with
promoter regions of these CXC chemokine genes. How-
ever, it has been clearly shown that TLR4 signaling via
MyD88 also induces MCP-1, MIP1a, MIP1b, IP-10, and
MCP5 expression (Kopydlowski et al., 1999). In view of
observations that IL-1R-deficient mice do develop
chronic inflammatory lesions over longer periods, it re-
mains to be determined how S. aureus preferentially in-
duces IL-1 mediated neutrophil responses.
The authors optimistically propose that the IL-1R-
MyD88 pathway may provide a local therapeutic target.
Aside from the use of antibiotics to reduce the inciting
microbial infection, this is difficult to envision. However,
topical administration of IL-1RA may prove helpful.
Overall, the scientific observations point out the pivotal
role of IL-1 in certain innate and adaptive immune re-
sponses. The findings enable us to better appreciatethe importance of the decoy IL-1RII and IL-1RA in regu-
lating the potentially self-destructive inflammatory con-
sequences of IL-1.
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